haloperidol has been researched along with Neoplasms in 61 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment of delirium often includes haloperidol." | 9.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 9.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016." | 9.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 9.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| "Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage." | 9.08 | Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996) |
| "This was a preplanned secondary analysis of a double-blind randomized clinical trial examining the sedative effect of chlorpromazine and/or haloperidol in patients with agitated delirium." | 5.41 | Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication. ( Bruera, E; De La Rosa, A; Hui, D; Nguyen, T; Urbauer, DL, 2021) |
| "Treatment of delirium often includes haloperidol." | 5.34 | Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial. ( Beeker, A; Beekman, ATF; Berkhof, J; Boddaert, MSA; Neefjes, ECW; Teunissen, SCC; van der Vorst, MJDL; Verdegaal, BATT; Verheul, HMW; Wilschut, JA; Zuurmond, WWA, 2020) |
| "The purpose of the study was to compare efficacy and toxicity of olanzapine (OLN; a higher-cost drug) and haloperidol (HAL; a lower-cost drug) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients who receive highly emetogenic chemotherapy (HEC)." | 5.30 | Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal. ( Acharya, B; Dulal, S; Neupane, P; Paudel, BD; Poudyal, BS; Shah, A; Shilpakar, R; Wood, LA, 2019) |
| "The current study was a secondary analysis of a randomized controlled trial to compare the effect of lorazepam versus placebo as an adjuvant to haloperidol for persistent agitation in patients with delirium." | 5.27 | The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. ( Arthur, J; Bruera, E; Dalal, S; Dev, R; Dibaj, SS; Hess, K; Hui, D; Reddy, S, 2018) |
| "Single-center, double-blind, parallel-group, randomized clinical trial conducted at an acute palliative care unit at MD Anderson Cancer Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled haloperidol from February 11, 2014, to June 30, 2016, with data collection completed in October 2016." | 5.24 | Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. ( Amin, S; Breitbart, W; Bruera, E; De La Cruz, M; Delgado-Guay, M; Dibaj, SS; Epner, D; Frisbee-Hume, S; Hall, S; Hess, K; Hui, D; Liu, D; Nguyen, T; Reddy, A; Tanco, K; Vidal, M; Walker, P; Williams, J; Wilson, A; Zhukovsky, DS, 2017) |
| "The topical gel known as "ABH gel," comprising lorazepam (Ativan(®)), diphenhydramine (Benadryl(®)), and haloperidol (Haldol(®)), is frequently used to treat nausea because of its perceived efficacy, relatively low cost, and ease of use in the home setting." | 5.19 | A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea. ( Coyne, PJ; Dodson, PW; Fletcher, DS; Parker, GG; Smith, TJ; Wan, W, 2014) |
| "Haloperidol is used commonly for the control of nausea and vomiting (N/V) in palliative care patients, but there is very little evidence to support its use." | 5.14 | The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer. ( Douglas, C; Gilshenan, K; Hardy, JR; O'Shea, A; Welch, L; White, C, 2010) |
| "Although haloperidol is mainly used for the medical treatment of delirium in cancer patients, there are no universally accepted guidelines for its usage." | 5.08 | Usage of haloperidol for delirium in cancer patients. ( Akechi, T; Fukue, M; Kagaya, A; Nishida, A; Okamura, H; Oomori, N; Uchitomi, Y; Yamawaki, S, 1996) |
| "Metoclopramide is an effective antiemetic for cisplatin-induced vomiting when given in parenteral high-dose regimens but not oral low-dose regimens." | 5.05 | Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. ( Cariffe, P; Gala, KV; Grunberg, SM; Jamin, D; Johnson, K; Krailo, M; Lampenfeld, M; Strych, D, 1984) |
| " Inquiries were made regarding: (i) choice of drug class in the first-line treatment, (ii) administration methods of the first-line antipsychotic treatment, (iii) starting dose of antipsychotics in the first line treatment and maximum dose of antipsychotics in refractory delirium, and (iv) choice of treatment when the first-line haloperidol treatment failed." | 4.12 | Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists. ( Kashiwagi, H; Matsuda, Y; Morita, T; Naito, AS; Otani, H; Oya, K; Tagami, K, 2022) |
| "To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS)." | 3.83 | Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study. ( Goya, S; Kai, T; Kanemura, S; Kashiwagi, Y; Maeda, I; Matsuda, Y; Nakajima, S; Okamoto, Y; Taira, T; Takei, K; Tanimukai, H; Tokoro, A; Tokuyama, M; Tsujimoto, H; Tsujio, I; Watanabe, M, 2016) |
| "More than 2,000 medically ill patients with delirium have been treated by intravenous administration of a combination of haloperidol and lorazepam." | 3.67 | Emergency intravenous sedation of the delirious, medically ill patient. ( Adams, F, 1988) |
| "A case of agitated delirium secondary to bilateral occipital cerebral infarctions in a cancer patient was refractory to trials of large doses of intravenous psychotropic agents, but continuous intravenous infusion of haloperidol controlled agitation rapidly and safely." | 3.67 | Treatment of severe, refractory agitation with a haloperidol drip. ( Adams, F; Fernandez, F; Holmes, VF; Kavanaugh, JJ, 1988) |
| "Eleven patients with various cancer types from ten case reports published from 1988 to 2013 met the eligibility criteria." | 2.66 | Neuroleptic malignant syndrome in patients with cancer: a systematic review. ( Ishida, M; Kawakami, K; Kawanishi, C; Onishi, H; Sato, I; Yamada, S, 2020) |
| "Delirium is the most common and distressing neuropsychiatric syndrome in cancer patients." | 2.53 | Neuroleptics in the management of delirium in patients with advanced cancer. ( Bruera, E; Dev, R; Hui, D, 2016) |
| "Delirium is common in the last weeks of life, occurring in 26% to 44% of people with advanced cancer in hospital, and in up to 88% of people with terminal illness in the last days of life." | 2.45 | Delirium at the end of life. ( Keeley, PW, 2009) |
| "Delirium is the second most common psychiatric diagnosis among hospitalized elderly cancer patients." | 2.38 | Delirium in cancer patients. ( Holland, J; Stiefel, F, 1991) |
| " Limited information is available regarding the dosage requirements and efficacy of neuroleptics in the palliative care setting." | 1.36 | Neuroleptic dose in the management of delirium in patients with advanced cancer. ( Bruera, E; Bush, SH; Gallo, LE; Hui, D; Palmer, JL; Yennurajalingam, S, 2010) |
| "Haloperidol has been found to be very efficient in controlling agitation with or without pain, nausea and/or vomiting of central origin, intestinal obstruction, and delirium." | 1.33 | Stability of tramadol and haloperidol for continuous subcutaneous infusion at home. ( Azuara, ML; Barcia, E; Martín, A; Negro, S; Sánchez, Y, 2005) |
| "Haloperidol was precipitated at a concentration of >/=1." | 1.32 | Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. ( Barcia, E; Luz Azuara, M; Negro, S; Reyes, R; Sánchez, Y, 2003) |
| "At the time of peak hyperalgesia, WIN55,212-2 (1-30mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0." | 1.32 | A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. ( Croft, DL; Hamamoto, DT; Kehl, LJ; Norsted, BD; Simone, DA; Wacnik, PW; Wilcox, GL, 2003) |
| " The mean dosage for midazolam was 18." | 1.32 | Use of sedation to relieve refractory symptoms in dying patients. ( Blitz-Lindeque, J; Bridge, D; Cameron, D, 2004) |
| "Depression in cancer patients is common and occurs throughout the course of cancer illness." | 1.31 | [Management of psychiatric symptoms in cancer patients]. ( Uchitomi, Y, 2002) |
| "Delirium in the cancer patient is particularly problematic given the coexisting medical problems these patients experience." | 1.29 | A retrospective study of the psychiatric management and outcome of delirium in the cancer patient. ( Baile, WF; Meyers, CA; Olofsson, SM; Valentine, AD; Weitzner, MA, 1996) |
| "20 patients with neuropathic pain syndromes due to tumor-infiltration, who had not responded to conventional analgesics including strong opioids, received additional combination anti-convulsant and anti-depressant treatment." | 1.28 | Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients. ( Höffken, K; Kloke, M; Olbrich, H; Schmidt, CG, 1991) |
| " A dosing strategy for the combbination of clomipramine and haloperidol is described." | 1.26 | [The treatment of chronic pain symptoms with psychotropic drugs (author's transl)]. ( Kocher, R, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (26.23) | 18.7374 |
| 1990's | 7 (11.48) | 18.2507 |
| 2000's | 12 (19.67) | 29.6817 |
| 2010's | 20 (32.79) | 24.3611 |
| 2020's | 6 (9.84) | 2.80 |
| Authors | Studies |
|---|---|
| John, CS | 1 |
| Lim, BB | 1 |
| Vilner, BJ | 1 |
| Geyer, BC | 1 |
| Bowen, WD | 1 |
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Mach, RH | 1 |
| Zeng, C | 1 |
| Hawkins, WG | 1 |
| Weber, F | 1 |
| Brune, S | 1 |
| Korpis, K | 1 |
| Bednarski, PJ | 1 |
| Laurini, E | 1 |
| Dal Col, V | 1 |
| Pricl, S | 1 |
| Schepmann, D | 1 |
| Wünsch, B | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Lindsley, CW | 1 |
| Hopkins, CR | 1 |
| Amata, E | 1 |
| Dichiara, M | 1 |
| Arena, E | 1 |
| Pittalà, V | 1 |
| Pistarà, V | 1 |
| Cardile, V | 1 |
| Graziano, ACE | 1 |
| Fraix, A | 1 |
| Marrazzo, A | 1 |
| Sortino, S | 1 |
| Prezzavento, O | 1 |
| Matsuda, Y | 2 |
| Morita, T | 1 |
| Oya, K | 1 |
| Tagami, K | 1 |
| Naito, AS | 1 |
| Kashiwagi, H | 1 |
| Otani, H | 1 |
| van der Vorst, MJDL | 1 |
| Neefjes, ECW | 1 |
| Boddaert, MSA | 1 |
| Verdegaal, BATT | 1 |
| Beeker, A | 1 |
| Teunissen, SCC | 1 |
| Beekman, ATF | 1 |
| Wilschut, JA | 1 |
| Berkhof, J | 1 |
| Zuurmond, WWA | 1 |
| Verheul, HMW | 1 |
| Sato, I | 1 |
| Onishi, H | 1 |
| Kawanishi, C | 1 |
| Yamada, S | 1 |
| Ishida, M | 1 |
| Kawakami, K | 1 |
| Hui, D | 7 |
| De La Rosa, A | 2 |
| Wilson, A | 2 |
| Nguyen, T | 3 |
| Wu, J | 1 |
| Delgado-Guay, M | 2 |
| Azhar, A | 1 |
| Arthur, J | 2 |
| Epner, D | 2 |
| Haider, A | 1 |
| De La Cruz, M | 2 |
| Heung, Y | 1 |
| Tanco, K | 2 |
| Dalal, S | 2 |
| Reddy, A | 3 |
| Williams, J | 2 |
| Amin, S | 2 |
| Armstrong, TS | 1 |
| Breitbart, W | 2 |
| Bruera, E | 7 |
| Zhu, J | 1 |
| Xiong, Y | 1 |
| Zhang, Y | 1 |
| Wen, J | 1 |
| Cai, N | 1 |
| Cheng, K | 1 |
| Liang, H | 1 |
| Zhang, W | 1 |
| Urbauer, DL | 1 |
| Frisbee-Hume, S | 1 |
| Dibaj, SS | 2 |
| Walker, P | 1 |
| Zhukovsky, DS | 1 |
| Vidal, M | 1 |
| Hall, S | 1 |
| Liu, D | 1 |
| Hess, K | 2 |
| Dev, R | 2 |
| Reddy, S | 1 |
| Shrikant Kulkarni, N | 1 |
| Dulal, S | 1 |
| Paudel, BD | 1 |
| Neupane, P | 1 |
| Shah, A | 1 |
| Acharya, B | 1 |
| Poudyal, BS | 1 |
| Shilpakar, R | 1 |
| Wood, LA | 1 |
| Fletcher, DS | 1 |
| Coyne, PJ | 1 |
| Dodson, PW | 1 |
| Parker, GG | 1 |
| Wan, W | 1 |
| Smith, TJ | 1 |
| Tanimukai, H | 1 |
| Tsujimoto, H | 1 |
| Tokoro, A | 1 |
| Kanemura, S | 1 |
| Watanabe, M | 1 |
| Tsujio, I | 1 |
| Maeda, I | 1 |
| Takei, K | 1 |
| Nakajima, S | 1 |
| Taira, T | 1 |
| Tokuyama, M | 1 |
| Kai, T | 1 |
| Okamoto, Y | 1 |
| Goya, S | 1 |
| Kashiwagi, Y | 1 |
| Boušová, I | 1 |
| Skálová, L | 1 |
| Souček, P | 1 |
| Matoušková, P | 1 |
| Bush, SH | 1 |
| Gallo, LE | 1 |
| Palmer, JL | 1 |
| Yennurajalingam, S | 1 |
| Hardy, JR | 1 |
| O'Shea, A | 1 |
| White, C | 1 |
| Gilshenan, K | 1 |
| Welch, L | 1 |
| Douglas, C | 1 |
| Keeley, PW | 1 |
| Palla, S | 1 |
| Radha Krishna, LK | 1 |
| Poulose, VJ | 1 |
| Goh, C | 1 |
| Kim, FJ | 1 |
| Schrock, JM | 1 |
| Spino, CM | 1 |
| Marino, JC | 1 |
| Pasternak, GW | 1 |
| Uchitomi, Y | 2 |
| Barcia, E | 3 |
| Reyes, R | 2 |
| Luz Azuara, M | 1 |
| Sánchez, Y | 3 |
| Negro, S | 3 |
| Kehl, LJ | 1 |
| Hamamoto, DT | 1 |
| Wacnik, PW | 1 |
| Croft, DL | 1 |
| Norsted, BD | 1 |
| Wilcox, GL | 1 |
| Simone, DA | 1 |
| Cameron, D | 1 |
| Bridge, D | 1 |
| Blitz-Lindeque, J | 1 |
| Martín, A | 1 |
| Azuara, ML | 2 |
| Guo, SL | 1 |
| Lin, CJ | 1 |
| Huang, HH | 1 |
| Chen, LK | 1 |
| Sun, WZ | 1 |
| Ito, H | 1 |
| Harada, D | 1 |
| Hayashida, K | 1 |
| Ishino, H | 1 |
| Nakayama, K | 1 |
| Bleicher, J | 1 |
| Bhaskara, A | 1 |
| Huyck, T | 1 |
| Constantino, S | 1 |
| Bardia, A | 1 |
| Loprinzi, CL | 1 |
| Silberstein, PT | 1 |
| Grunberg, SM | 1 |
| Gala, KV | 1 |
| Lampenfeld, M | 1 |
| Jamin, D | 1 |
| Johnson, K | 1 |
| Cariffe, P | 1 |
| Strych, D | 1 |
| Krailo, M | 1 |
| Breivik, H | 1 |
| Rennemo, F | 1 |
| Olofsson, SM | 1 |
| Weitzner, MA | 1 |
| Valentine, AD | 1 |
| Baile, WF | 1 |
| Meyers, CA | 1 |
| Akechi, T | 1 |
| Okamura, H | 1 |
| Fukue, M | 1 |
| Kagaya, A | 1 |
| Nishida, A | 1 |
| Oomori, N | 1 |
| Yamawaki, S | 1 |
| Mickle, J | 1 |
| Critchley, P | 1 |
| Plach, N | 1 |
| Grantham, M | 1 |
| Marshall, D | 1 |
| Taniguchi, A | 1 |
| Latimer, E | 1 |
| Jadad, AR | 1 |
| Kocher, R | 2 |
| Ottesen, S | 1 |
| Monrad, L | 1 |
| Stiefel, F | 1 |
| Holland, J | 1 |
| Kloke, M | 1 |
| Höffken, K | 1 |
| Olbrich, H | 1 |
| Schmidt, CG | 1 |
| Adams, F | 3 |
| Murakami, M | 1 |
| Ota, K | 1 |
| Fernandez, F | 2 |
| Holmes, VF | 1 |
| Kavanaugh, JJ | 1 |
| Andersson, BS | 1 |
| Maisami, M | 1 |
| Sohmer, BH | 1 |
| Coyle, JT | 1 |
| Saller, R | 1 |
| Hellenbrecht, D | 1 |
| Plotkin, DA | 1 |
| Plotkin, D | 1 |
| Okun, R | 1 |
| Sirtori, C | 1 |
| Cole, DR | 1 |
| Duffy, DF | 1 |
| Rohrer, G | 1 |
| Aydın, M | 1 |
| Tóth, Z | 1 |
| Czoma, V | 1 |
| Bittersohl, G | 1 |
| Bittersohl, J | 1 |
| Iavorovskiĭ, AP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer[NCT01539733] | 101 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit[NCT03021486] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2017-06-05 | Active, not recruiting | ||
| A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit[NCT01949662] | Phase 2 | 93 participants (Actual) | Interventional | 2014-01-31 | Active, not recruiting | ||
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023] | Phase 3 | 72 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | ||
| Open-label Randomized Controlled Trial of Oral Transmucosal Haloperidol and Olanzapine in the Treatment of Terminal Delirium[NCT04750395] | Phase 2 | 80 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 30 minutes later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 30 minutes later.
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -2.6 |
| Rotation Group | -2.4 |
| Combination Group | -2.1 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The primary outcome was mean change in RASS score between time 0 (immediately before initiation of masked treatment) and 24 h later. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours after study medication administration
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -3.6 |
| Rotation Group | -3.3 |
| Combination Group | -3.0 |
The Memorial Delirium Assessment Scale (MDAS) is a 10-item clinician-rated assessment scale validated for assessment of delirium in cancer patients. It examines the level of consciousness, disorientation, memory, recall, attention, disorganized thinking, perceptual disturbance, delusions, psychomotor activity and sleep, assigning a score between 0 to 3, for a total score between 0-30. A total score of 13 or higher indicates delirium. We measured the change in Memorial Delirium Rating scale between baseline and 24 hours. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Escalation Group | -2.7 |
| Rotation Group | 1 |
| Combination Group | 0.3 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The secondary outcome was the proportion of breakthrough restlessness participants with a RASS score of >=1 during the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid oversedation in the Intensive Care Unit. (NCT03021486)
Timeframe: 0 or Baseline and 24 hours later
| Intervention | Participants (Count of Participants) |
|---|---|
| Escalation Group | 12 |
| Rotation Group | 7 |
| Combination Group | 9 |
RASS score is a 10-point scale with scores ranging from +4 (very combative, violent) to -5 (unarousable). The Secondary outcome was the percentage of participants with target RASS score of -2 to 0 within the first 24 hours. The Richmond Agitation-Sedation Scale (RASS) was developed by a multidisciplinary team at Virginia Commonwealth University in Richmond; it is a validated method used to avoid over sedation in the Intensive Care Unit. (NCT03021486)
Timeframe: Time 0 or Baseline and 24 hours later.
| Intervention | Participants (Count of Participants) |
|---|---|
| Escalation Group | 2 |
| Rotation Group | 3 |
| Combination Group | 5 |
This 14-item questionnaire examines both the recalled frequency of 7 delirium symptoms and associated distress in the rater: disorientation to time, disorientation to place, visual hallucinations, tactile hallucinations, auditory hallucinations, delusional thoughts and psychomotor agitation. The score for recalled frequency ranges between 0 and 4, where 0=not present, 1=a little of the time, 2=some of the time, 3=good part of the time, and 4=most or all of the time. The score for distress in the rater related to each delirium symptom also ranges from 0 to 4, where 0=no distress, 1=a little, 2=a fair amount, 3=very much and 4=extremely distressed. Due to an error in the data collection form, the last category was omitted as a choice and thus the score only ranged from 0 to 3. (NCT03021486)
Timeframe: Baseline and Day 3
| Intervention | score on a scale (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nursing assessment, disorientation to time - frequency | Nursing assessment, disorientation to place - frequency | Nursing assessment, visual hallucination - frequency | Nursing assessment, tactile hallucination - frequency | Nursing assessment, auditory hallucination - frequency | Nursing assessment, delusional thoughts - frequency | Nursing assessment, psychomotor agitation- frequency | Nursing assessment, disorientation to time - distress | Nursing assessment, disorientation to place - distress | Nursing assessment, visual hallucination - distress | Nursing assessment, tactile hallucination - distress | Nursing assessment, auditory hallucination - distress | Nursing assessment, delusional thoughts - distress | Nursing assessment, psychomotor agitation - distress | |
| Combination Group | 0.2 | 0.3 | -0.7 | -0.9 | -0.4 | 0.2 | -0.4 | -0.5 | -0.4 | -0.4 | -0.5 | -0.2 | -0.1 | -0.8 |
| Escalation Group | -0.8 | -0.9 | -1 | -0.4 | -0.1 | -0.8 | -1.2 | -0.3 | -0.3 | -0.6 | -0.5 | -0.3 | -0.6 | -0.8 |
| Rotation Group | -0.8 | -0.8 | 0 | 0.1 | 0.1 | 0 | -0.8 | -0.3 | -0.3 | 0.1 | 0 | 0 | 0 | -0.5 |
Edmonton Symptom Assessment System (ESAS) has been validated and widely used in different clinical settings, including the acute palliative care unit. It assessed the average symptom intensity of 10 symptoms over the past 24 hours. Each symptom was assessed using an 11-point numeric rating scale, ranging from 0 (none) to 10 (worst). It was measured as change in ESAS as Perceived by Caregivers between baseline and day 1, mean. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | score on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pain | Fatigue | Nausea | Depression | Anxiety | Drowsiness | Appetite | Feeling of well being* | Shortness of breath | Sleep | |
| Combination Group | -1.1 | 1 | -0.4 | -0.8 | -0.9 | 0.7 | 0.1 | 0 | 0 | -2.7 |
| Escalation Group | -1.3 | -0.5 | 0.1 | -1.4 | -1.5 | -0.2 | -0.3 | 0.2 | 0.8 | -2.7 |
| Rotation Group | -4.1 | -3 | -1.8 | -1.2 | -4.8 | -0.6 | -0.6 | -1.6 | -2.2 | -5.1 |
Use of neuroleptics and benzodiazepines during the first 24 hours was retrieved from the Medication Administration Record. (NCT03021486)
Timeframe: Baseline and 24 hours
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Need for study med dose escalation in first 24 hrs | Benzodiazepine use in first 24 hrs (scheduled) | Benzodiazepine use in first 24 hrs (as needed) | |
| Combination Group | 7 | 0 | 4 |
| Escalation Group | 4 | 1 | 0 |
| Rotation Group | 1 | 0 | 0 |
"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Perceived To Have A High Level of Comfort (More Comfortable) | Perceived To Have A Low Level of Agitation (Less Agitated) | |
| Combination Group | 6 | 6 |
| Escalation Group | 8 | 9 |
| Rotation Group | 10 | 10 |
"On day 1 (after initiation of blinded treatment), we asked the blinded caregivers to provide their overall impression of change in patient comfort level and the agitation level. The response ranged from strongly agree, agree, neutral, disagree, and strongly disagree. In this study, strongly agree and agree were combined for analysis. The participants who reported 'Agree' and 'Strongly Agree' responses to perceived comfort level have a high level of comfort (more comfortable). And similarly, the participants who reported 'Agree' and 'Strongly Agree' responses to perceived agitation level have a low level of agitation (less agitated)." (NCT03021486)
Timeframe: Baseline and 24 hour
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Perceived To Have A High Level of Comfort (More Comfortable) | Perceived To Have A Low Level of Agitation (Less Agitated) | |
| Combination Group | 7 | 7 |
| Escalation Group | 9 | 8 |
| Rotation Group | 9 | 8 |
We also documented the selected adverse effects associated with neuroleptics using the Udvalg for Kliniske Undersogelser (UKU) side effects rating scale. Specifically, we assessed 8 neurologic symptoms (dystonia, rigidity, hypokinesia/akinesia, hyperkinesia, tremor, akathisia, epileptic seizures, paraesthesias). We are reporting only the neurologic symptoms (tremor and akathisia) that had changes during the study. Each item was assigned a score by the research coordinator 0 (absent) to 3 (most severe) based on symptom severity of the last 3 days. (NCT03021486)
Timeframe: Baseline and 3 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Tremor (decreased) | Akathisia (decreased) | |
| Combination Group | 1 | 1 |
| Escalation Group | 0 | 0 |
| Rotation Group | 0 | 0 |
Absolute score of Richmond Agitation-Sedation Scale at 8 hr, points. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -2.5 |
| Control Group (Placebo & Haloperidol) | -0.7 |
The primary outcome was change in Richmond Agitation-Sedation Scale score from baseline to 8 hours after treatment administration. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -4.1 |
| Control Group (Placebo & Haloperidol) | -2.3 |
Change in Richmond Agitation-Sedation Scale score from baseline to 30 min. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 30 minutes
| Intervention | score on a scale (Mean) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | -3.6 |
| Control Group (Placebo & Haloperidol) | -1.6 |
Number of participants with Richmond Agitation-Sedation Scale score >=1 within 8 hr. Richmond Agitation-Sedation Score ranged from -5 (unarousable) to +4 (very agitated) , where 0 denotes a calm and alert patient. (NCT01949662)
Timeframe: Baseline to 8 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention Group (Lorazepam & Haloperidol) | 8 |
| Control Group (Placebo & Haloperidol) | 22 |
13 reviews available for haloperidol and Neoplasms
| Article | Year |
|---|---|
The σ2 receptor: a novel protein for the imaging and treatment of cancer.
Topics: Animals; Cell Proliferation; Drug Discovery; Humans; Molecular Imaging; Molecular Probes; Neoplasms; | 2013 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Return of D
Topics: Animals; Drug Discovery; Humans; Ligands; Molecular Targeted Therapy; Neoplasms; Parkinson Disease; | 2017 |
Neuroleptic malignant syndrome in patients with cancer: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Dantrolene; Dopamine D2 Receptor Antagonists; | 2020 |
The Molecular Mechanisms of Regulating Oxidative Stress-Induced Ferroptosis and Therapeutic Strategy in Tumors.
Topics: Acetaminophen; Antineoplastic Agents; Antioxidants; Apoptosis; Artemisinins; Auranofin; Cell Death; | 2020 |
The modulation of carbonyl reductase 1 by polyphenols.
Topics: Alcohol Oxidoreductases; Animals; Bupropion; Butanones; Butyrophenones; Daunorubicin; Doxorubicin; G | 2015 |
Neuroleptics in the management of delirium in patients with advanced cancer.
Topics: Antipsychotic Agents; Delirium; Dose-Response Relationship, Drug; Drug Therapy, Combination; Haloper | 2016 |
Delirium at the end of life.
Topics: Analgesics, Opioid; Antipsychotic Agents; Barbiturates; Delirium; Haloperidol; Humans; Incidence; Ne | 2009 |
Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms; Palliative Care; Vomiting | 2001 |
Delirium in cancer patients.
Topics: Aged; Delirium; Diagnosis, Differential; Haloperidol; Humans; Lorazepam; Neoplasms; Neuropsychologic | 1991 |
[Recent advances in the management of chemotherapy-induced emesis].
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Dexamethasone; Domperidone; Dronabinol; Drug Therapy, | 1986 |
[The genotoxic effect of epichlorohydrin and epoxy resins].
Topics: Berlin; Chlorohydrins; Epichlorohydrin; Epoxy Resins; Female; Humans; Male; Mutation; Neoplasms; Occ | 1989 |
[Problems of work hygiene and toxicology in the present-day manufacture of plastics of an epoxy resin base (review of the literature)].
Topics: Air Pollutants, Occupational; Animals; Chemical Industry; Dermatitis, Contact; Dermatitis, Occupatio | 1986 |
14 trials available for haloperidol and Neoplasms
| Article | Year |
|---|---|
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Neoplasms; Olanzapine; | 2020 |
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial.
Topics: Aged; Antipsychotic Agents; Delirium; Double-Blind Method; Female; Follow-Up Studies; Haloperidol; H | 2020 |
Personalized sedation goal for agitated delirium in patients with cancer: Balancing comfort and communication.
Topics: Communication; Delirium; Goals; Haloperidol; Humans; Hypnotics and Sedatives; Intensive Care Units; | 2021 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Double-Blind Me | 2017 |
The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium.
Topics: Adult; Aged; Aged, 80 and over; Delirium; Drug Therapy, Combination; Female; Haloperidol; Humans; Lo | 2018 |
Lorazepam Added to Haloperidol Effective for Agitated Delirium in End-of-Life Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Drug Therapy, Combination; Female; H | 2018 |
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemo | 2019 |
A randomized trial of the effectiveness of topical "ABH Gel" (Ativan(®), Benadryl(®), Haldol(®)) vs. placebo in cancer patients with nausea.
Topics: Administration, Topical; Adolescent; Adult; Aged; Antiemetics; Cross-Over Studies; Diphenhydramine; | 2014 |
The efficacy of haloperidol in the management of nausea and vomiting in patients with cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Female; Ha | 2010 |
Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Drug Evaluati | 1984 |
Usage of haloperidol for delirium in cancer patients.
Topics: Aged; Delirium; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guidelines a | 1996 |
[Benefit and risk of high-dose metoclopramide in comparison to high-dose haloperidol or triflupromazine in cisplatin-induced vomiting].
Topics: Cisplatin; Dose-Response Relationship, Drug; Haloperidol; Humans; Metoclopramide; Neoplasms; Risk; T | 1985 |
Haloperidol for radiation sickness: Control of associated nausea, vomiting, and anorexia.
Topics: Adult; Aged; Clinical Trials as Topic; Feeding and Eating Disorders; Female; Haloperidol; Humans; Ma | 1974 |
[Treatment of severe chronic pains with a combination of thymoleptics and neuroleptics (author's transl)].
Topics: Adult; Antidepressive Agents; Atropine; Chlorpromazine; Clinical Trials as Topic; Clomipramine; Drug | 1974 |
34 other studies available for haloperidol and Neoplasms
| Article | Year |
|---|---|
Substituted halogenated arylsulfonamides: a new class of sigma receptor binding tumor imaging agents.
Topics: Animals; Binding, Competitive; Brain; Guinea Pigs; Iodine Radioisotopes; Isotope Labeling; Ligands; | 1998 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Synthesis, pharmacological evaluation, and σ1 receptor interaction analysis of hydroxyethyl substituted piperazines.
Topics: Animals; Antineoplastic Agents; Apoptosis; Brain; Chromatography, Thin Layer; Guinea Pigs; Humans; M | 2014 |
Novel Sigma Receptor Ligand-Nitric Oxide Photodonors: Molecular Hybrids for Double-Targeted Antiproliferative Effect.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Humans; Light; MCF-7 Cells; Neo | 2017 |
Current practice of pharmacological treatment for hyperactive delirium in terminally ill cancer patients: results of a nationwide survey of Japanese palliative care physicians and liaison psychiatrists.
Topics: Antipsychotic Agents; Benzodiazepines; Delirium; Haloperidol; Humans; Japan; Neoplasms; Palliative C | 2022 |
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cross-Sectional Studies; Delirium; F | 2016 |
Neuroleptic dose in the management of delirium in patients with advanced cancer.
Topics: Adult; Affective Symptoms; Aged; Aged, 80 and over; Algorithms; Antipsychotic Agents; Delirium; Dose | 2010 |
Neuroleptic prescription pattern for delirium in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; Male; M | 2011 |
The use of midazolam and haloperidol in cancer patients at the end of life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Haloperidol; Humans; Hypnoti | 2012 |
Inhibition of tumor cell growth by Sigma1 ligand mediated translational repression.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Size; Haloperidol; Humans; Ligands; Morpholines; Neoplasm | 2012 |
[Management of psychiatric symptoms in cancer patients].
Topics: Antidepressive Agents; Delirium; Depression; Disease Management; Dopamine Antagonists; Haloperidol; | 2002 |
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care.
Topics: Antiemetics; Butylscopolammonium Bromide; Drug Interactions; Drug Stability; Drug Storage; Haloperid | 2003 |
A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Topics: Animals; Benzoxazines; Calcium Channel Blockers; Camphanes; Cannabinoids; Carrageenan; Catalepsy; Di | 2003 |
Use of sedation to relieve refractory symptoms in dying patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Communication; Conscious Sedatio | 2004 |
Stability of tramadol and haloperidol for continuous subcutaneous infusion at home.
Topics: Analgesics, Opioid; Antipsychotic Agents; Chemical Phenomena; Chemistry, Physical; Drug Combinations | 2005 |
Reversal of morphine with naloxone precipitates haloperidol-induced extrapyramidal side effects.
Topics: Adolescent; Analgesics, Opioid; Antipsychotic Agents; Basal Ganglia Diseases; Drug Interactions; Fem | 2006 |
[Psychiatry and sleep disorders--delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperidol; Humans; I | 2006 |
Lorazepam, diphenhydramine, and haloperidol transdermal gel for rescue from chemotherapy-induced nausea/vomiting: results of two pilot trials.
Topics: Administration, Cutaneous; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Clini | 2008 |
Clinical evaluation of combined treatment with methadone and psychotropic drugs in cancer patients.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Methadone; Middle Aged; M | 1982 |
A retrospective study of the psychiatric management and outcome of delirium in the cancer patient.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antipsychotic Agents; Delirium; Female; Haloperido | 1996 |
The use of haloperidol to treat nausea.
Topics: Antiemetics; Haloperidol; Humans; Nausea; Neoplasms | 1998 |
Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Butylscopolammonium Bromide; Dexamethasone; Drug Evaluat | 2002 |
[The treatment of chronic pain symptoms with psychotropic drugs (author's transl)].
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bone Diseases; Clomipramine; Drug Therapy, C | 1976 |
[Morphine-antiemetics mixtures for continuous subcutaneous infusion in terminal cancer].
Topics: Antiemetics; Drug Combinations; Drug Stability; Haloperidol; Humans; Infusion Pumps, Implantable; Me | 1992 |
Anti-depressants and anti-convulsants for the treatment of neuropathic pain syndromes in cancer patients.
Topics: Analgesics; Anticonvulsants; Antidepressive Agents; Clomipramine; Drug Therapy, Combination; Haloper | 1991 |
Emergency intravenous sedation of the delirious, medically ill patient.
Topics: Critical Care; Delirium; Drug Therapy, Combination; Haloperidol; Humans; Hydromorphone; Infusions, I | 1988 |
Treatment of severe, refractory agitation with a haloperidol drip.
Topics: Acute Disease; Cerebral Infarction; Delirium; Female; Haloperidol; Humans; Infusions, Intravenous; M | 1988 |
Emergency pharmacotherapy of delirium in the critically ill cancer patient.
Topics: Adult; Aged; Delirium; Drug Therapy, Combination; Emergencies; Female; Haloperidol; Humans; Infusion | 1986 |
Combined use of tricyclic antidepressants and neuroleptics in the management of terminally ill children: a report on three cases.
Topics: Adolescent; Amitriptyline; Anxiety Disorders; Child; Depressive Disorder; Drug Therapy, Combination; | 1985 |
Haloperidol in the treatment of nausea and vomiting due to cytotoxic drug administration.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Female; Haloperidol; Humans; Male; Middle Aged; N | 1973 |
[Collecting of the news].
Topics: Aging; Air Pollution; Haloperidol; Health Education; Humans; Italy; Myocardial Infarction; Neoplasms | 1974 |
A sensitive and selective approach for detection of IL 1α cancer biomarker using disposable ITO electrode modified with epoxy-substituted polythiophene polymer.
Topics: Antibodies, Immobilized; Biomarkers, Tumor; Biosensing Techniques; Dielectric Spectroscopy; Epoxy Re | 2019 |
Immunohistochemistry on epoxy resin-embedded bone marrow biopsy experience with 936 cases.
Topics: Biopsy; Bone Marrow; Case-Control Studies; Epoxy Resins; Female; Humans; Immunohistochemistry; Male; | 2011 |
Cancer and coal tar epoxy resins.
Topics: Coal Tar; Epoxy Resins; Humans; Neoplasms; Occupational Diseases; Respiratory Tract Neoplasms; Risk | 1989 |